Disposable Hemoperfusion Market Size, Share, Growth, And Industry Analysis, By Type (Charcoal Hemoperfusion, Certain Resins Hemoperfusion) By Application (Overdose, Specific Intoxications, Certain Autoimmune Diseases, Hepatic Encephalopathy, and Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

DISPOSABLE HEMOPERFUSION MARKET OVERVIEW

The Disposable Hemoperfusion Market globally is expected to be valued at USD 1.92 Billion in 2026. It is forecasted to increase to USD 7.25 Billion by 2035. This reflects a compound annual growth rate CAGR of 15.88% between 2026 to 2035.

Large amounts of the patient's blood may be run over an adsorbent material as part of a therapeutic procedure called hemoperfusion, which removes hazardous chemicals from the blood. Adsorption is a process in which molecules or particles of one substance become attracted to and retained on the surface of a solid material. Sorbents are the name for these solid substances. Disposable Because blood is pumped through a device outside of the patient's body during hemoperfusion, the procedure is frequently referred to as an extracorporeal type of treatment. In this paper, we calculate the hemoperfusion-related medical supplies.

Key Findings 

LATEST TRENDS

Increasing Demand from Various Applications to Foster Market Growth

The market is projected to be driven in the coming years by the increasing need for the treatment of autoimmune illnesses and the recent appearance of end users for hemoperfusion. Other market-driving variables include a minimal risk of infection, rising public and private investment, and technical developments. The market is expected to be driven in the coming years by rising demand from various applications, such as the treatment of autoimmune illnesses and liver failure, as well as the appearance of new end users for hemoperfusion. The other motivating considerations are a minimal risk of infection, technological breakthroughs, and rising public and private investment.

Download Free Sample to learn more about this report

DISPOSABLE HEMOPERFUSION MARKET SEGMENTATION

By Type

Based on type, the market is divided into Charcoal Hemoperfusion, Certain Resins Hemoperfusion.  

• Charcoal Hemoperfusion: Charcoal hemoperfusion holds 55% of the disposable hemoperfusion market by type. These devices use activated charcoal as an adsorbent for removing selected drugs and toxins from circulating blood. Charcoal cartridges are commonly used in emergency departments, intensive care units, and toxicology centers. Their broad adsorption characteristics support treatment for selected drug overdoses and acute poisoning cases. Hospitals value these devices for their established clinical use and compatibility with extracorporeal blood-treatment systems. Product demand is supported by emergency-care preparedness and the need for rapid toxin removal. Manufacturers are improving cartridge biocompatibility, flow performance, and blood-contact safety. The segment remains the leading type because of its recognized role in acute detoxification procedures.

• Certain Resins Hemoperfusion: Certain resins hemoperfusion accounts for 45% of the disposable hemoperfusion market by type. Resin cartridges use synthetic adsorbent materials designed to capture selected toxins, inflammatory mediators, and protein-bound substances. These devices are applied in certain intoxication, liver-support, autoimmune, and critical-care procedures. Hospitals select resin-based cartridges when targeted adsorption and broader molecular selectivity are required. Demand is rising alongside clinical interest in cytokine removal and extracorporeal organ-support therapies. Manufacturers are developing resin materials with improved hemocompatibility and adsorption performance. Specialized intensive care facilities and liver-treatment centers represent important end users. The segment benefits from continuing research into applications beyond conventional poisoning management.

By Application

Based on the application, the market is divided into Overdose, Specific Intoxications, Certain Autoimmune Diseases, Hepatic Encephalopathy, and Others.

• Overdose: Overdose applications account for 25% of the disposable hemoperfusion market by application. Hemoperfusion may be used for selected severe drug overdoses when the toxic substance can be effectively adsorbed by the cartridge. Emergency departments and intensive care units represent the primary treatment settings. The procedure supports extracorporeal removal of circulating toxins that respond poorly to conventional supportive care. Adoption depends on toxin characteristics, clinical condition, physician judgment, and cartridge availability. Hospitals maintain disposable cartridges as part of emergency toxicology preparedness. Demand is supported by the need for timely intervention in life-threatening intoxication cases. Overdose treatment remains one of the joint-leading application segments.

• Specific Intoxications: Specific intoxications represent 20% of the disposable hemoperfusion market by application. This segment includes selected pharmaceutical, chemical, pesticide, and industrial toxin exposures suitable for adsorption-based blood purification. Hemoperfusion is considered when the substance has properties that allow effective cartridge binding. Toxicology departments and specialized emergency units are the principal users. Clinical selection depends on toxin distribution, protein binding, patient stability, and available treatment alternatives. Resin and charcoal cartridges may be selected according to the substance requiring removal. Occupational and accidental poisoning cases contribute to product demand. The segment benefits from improved toxicology protocols and broader access to critical-care services.

• Certain Autoimmune Diseases: Certain autoimmune disease applications hold 15% of the disposable hemoperfusion market by application. Adsorption-based extracorporeal therapies may support selected patients by removing pathogenic antibodies, immune complexes, or inflammatory mediators. Treatment is generally performed in specialized hospitals under close clinical supervision. Nephrology, rheumatology, neurology, and intensive-care teams may participate in patient evaluation. Product demand depends on clinical evidence, disease severity, treatment availability, and physician assessment. Resin-based cartridges are particularly relevant where selective adsorption is required. Manufacturers are studying improved adsorbents designed for greater biocompatibility and molecular specificity. This segment remains specialized because hemoperfusion is not a standard treatment for every autoimmune condition.

• Hepatic Encephalopathy: Hepatic encephalopathy accounts for 25% of the disposable hemoperfusion market by application. Hemoperfusion can provide supportive blood purification for selected patients with severe liver dysfunction and circulating toxic metabolites. Intensive care units and liver-transplant centers represent the primary treatment environments. Adsorption cartridges may be integrated with other extracorporeal liver-support techniques according to patient needs. Clinical use focuses on reducing selected protein-bound toxins and inflammatory substances. Demand is supported by the burden of acute liver failure and advanced chronic liver disease. Hospitals prioritize cartridges offering reliable adsorption, blood compatibility, and straightforward system integration. Hepatic encephalopathy is the other joint-leading application segment within the market.

• Others: Other applications account for 15% of the disposable hemoperfusion market by application. This category includes selected sepsis, cytokine-removal, critical-care, environmental exposure, and investigational organ-support procedures. Intensive care teams may use adsorption cartridges as adjunctive therapy in carefully selected cases. Demand is influenced by clinical protocols, specialist availability, regulatory approval, and supporting evidence. Resin-based systems are gaining attention for removing inflammatory mediators from circulating blood. Hospitals evaluate treatment suitability according to patient condition and expected adsorption performance. Manufacturers continue conducting research to establish safety and effectiveness across emerging indications. This segment offers development opportunities but requires stronger clinical validation for broader routine adoption.

MARKET DYNAMICS

Driving Factors

Therapeutics and Personalized Procedure to Incite Market Growth

Large amounts of the patient's blood may be run over an adsorbent material as part of a therapeutic procedure called hemoperfusion, which removes hazardous chemicals from the blood. Adsorption is a process in which molecules or particles of one substance become attracted to and retained on the surface of a solid material. Sorbents are the name for these solid substances. Disposable Because blood is pumped through a device outside of the patient's body during hemoperfusion, the procedure is frequently referred to as an extracorporeal type of treatment.

Increasing Cases of Diabetes to Stimulate Market Growth

The growing occurrence of numerous viruses and disorders such as sepsis, renal failure, and liver cirrhosis which can be cured by hemoperfusion. The increasing demand for improved and more operative treatment possibilities for several diseases. Technical improvements in hemoperfusion devices and systems that provide enhanced presentation and effectiveness. The increasing number of patients who are overweight or have diabetes, both of which upsurge the danger of emerging organ failures. The rising healthcare spending by governments and private companies to upkeep examination on original treatments using hemoperfusion.

Restraining Factor

Side Effects to Hamper Market Growth

The market for disposable hemoperfusion is anticipated to face challenges in the years to come due to rising risks of blood coagulation, organ failure, the destruction of blood platelets, and restrictions brought on by high costs, a lack of public awareness, and solutes found in dialysis membranes. These factors are expected to impede disposable hemoperfusion market growth in coming years.

Expansion of Critical Care and Emergency Detoxification Units

Opportunity

The rising need for emergency detoxification and ICU care drives disposable hemoperfusion adoption. Global hospitals deployed 15,000 units in 2025, with North America representing 40%, Europe 30%, Asia-Pacific 25%, and Middle East & Africa 5%. Blood flow rates range 180–400 mL/min, treatment time 3–6 hours, and adsorbent capacity 1–5 g per cartridge, supporting overdose management, hepatic encephalopathy, and autoimmune therapies. Expansion of critical care beds, especially 20,000–25,000 ICU beds added globally in 2025, presents significant market opportunities for hospital procurement and specialized clinics.

High Costs and Limited Availability of Specialized Disposables

Challenge

Disposable hemoperfusion units require precise cartridges with 1–5 g adsorption capacity, blood flow rates 180–400 mL/min, and treatment durations 3–6 hours. North America accounts for 40% of affected units, Europe 30%, Asia-Pacific 25%, Middle East & Africa 5%, totaling 15,000 units in 2025. Limited manufacturing capacity and strict quality control increase costs, making access challenging for smaller hospitals. Skilled operators are required for cartridge preparation, anticoagulation management, and monitoring toxin removal, contributing to operational complexity in emergency and critical care settings.

• Download Free Sample to learn more about this report

•  

DISPOSABLE HEMOPERFUSION MARKET REGIONAL INSIGHTS

Increasing Demand from Healthcare Sector to Drive Market in North America

Asia Pacific is estimated to account for the most prominent disposable hemoperfusion market share. It is being driven internationally by the rising usage of adsorbent substance techniques to remove poisons and harmful compounds, investments in emerging economies (including India, China, Brazil, South East Asia, and Mexico), and rapid expansion in end-use industries. The dynamics of the market are expected to change in the near future due to increased usage of hemoperfusion in healthcare, such as providing supportive treatment before and after transplantation for patients only in case of liver failure. The risk of infection, blood clotting, platelet loss, and organ failure associated with hemoperfusion are some of the major obstacles preventing wider implementation of this method.

• North America

North America holds 35% of the global disposable hemoperfusion market. The region benefits from advanced hospital infrastructure and specialized intensive care facilities. Emergency departments increasingly use hemoperfusion for severe poisoning and drug-related complications. Hospitals are improving access to extracorporeal blood purification technologies. Clinical research supports wider evaluation of hemoperfusion in liver support and inflammatory conditions. Healthcare providers emphasize infection control, cartridge safety, and treatment monitoring. Strong reimbursement systems and specialist availability continue supporting regional adoption.

• Europe

Europe accounts for 27% of the global disposable hemoperfusion market. Established healthcare systems support the availability of intensive care and emergency toxicology services. Hospitals use hemoperfusion for selected poisoning cases and complex organ-support treatments. Germany, France, the United Kingdom, Italy, and Nordic countries remain important markets. Clinical guidelines and hospital protocols influence purchasing decisions. Manufacturers focus on biocompatible cartridges, reliable adsorption performance, and simplified treatment workflows. Research collaborations and transplantation programs are also strengthening demand.

• Asia-Pacific

Asia-Pacific represents 25% of the global disposable hemoperfusion market. Expanding hospital networks and rising healthcare investment are improving access to critical-care technologies. China, Japan, India, South Korea, and Southeast Asia are important adoption centers. Physicians are using hemoperfusion in selected intoxication, inflammatory, and liver-support applications. Growing intensive care capacity is creating demand for disposable cartridges and treatment systems. Local manufacturing is improving product availability and reducing procurement barriers. Training programs are helping healthcare professionals implement hemoperfusion more effectively.

• Middle East & Africa

Middle East and Africa hold 8% of the global disposable hemoperfusion market. Healthcare modernization is supporting the development of specialized hospitals and emergency-care facilities. Gulf countries are investing in advanced critical-care and blood-purification technologies. South Africa remains an important market because of its established tertiary-care infrastructure. Hemoperfusion is primarily used for poisoning management and selected organ-support applications. Hospitals are strengthening infection-control procedures and staff training. Medical tourism and private healthcare investment are also supporting regional equipment adoption.

• Rest of World

Rest of World contributes 5% of the global disposable hemoperfusion market. Demand is supported by gradual improvements in hospital capacity and critical-care services. Healthcare providers are increasing awareness of extracorporeal detoxification and adsorption-based therapies. Private hospitals are adding specialized equipment for emergency and intensive care departments. Procurement remains influenced by product availability, physician training, and treatment affordability. Regional distributors play an important role in supplying cartridges and compatible devices. Future adoption will depend on clinical education, infrastructure investment, and regulatory approvals.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Leading industry players are collaborating with other businesses in an effort to keep one step ahead of the competition. To diversify their product offerings, many businesses are now investing in the introduction of new products. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• Tianjin Zibo High Technology: Tianjin Zibo High Technology has supplied over 500,000 disposable hemoperfusion cartridges globally, supporting ICUs and critical care facilities in China and Europe.

• CytoSorbents: CytoSorbents provides over 420,000 hemoperfusion devices worldwide, focusing on cytokine adsorption therapy for sepsis and COVID-19 critical care patients.

List of Top Disposable Hemoperfusion Companies

• Baxter International (U.S.)
• Asahi Kasei Corporation (Japan)
• CytoSorbentsCompany 11 (U.S.)
• Kaneka Pharma (Tokyo)
• Toray Medical (Japan)
• Aier (U.S.)
• Tianjin Zibo High Technology (China)
• Biosun Corporation (U.S.)
• Kangbei Medical Device
• Jafron Biomedical (China)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.